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DOI: http://dx.doi.org/10.1016/j.hemonc.2015.06.006BACKGROUND AND OBJECTIVES: We undertook the present study to ascertain the contributing risk factors
and explore the epidemiological and mycological characteristics of opportunistic candidemia among patients
with hematological malignancies.
DESIGN AND SETTINGS: Observational cross-sectional study in a tertiary care center.
PATIENTS AND METHODS: Consecutive patients with hematological malignancies reporting to the collaborat-
ing medical and pediatric units with a febrile episode were recruited and screened for candidemia by blood cul-
ture. Recovered Candida isolates were speciated and antifungal susceptibility testing was performed as per
Clinical and Laboratory Standards Institute guideline (CLSI) guidelines M44-A. Further analysis was done for
potential risk factors and compared between culture positive and negative patients.
RESULTS: Of 150 patients recruited, the majority (n = 27) were between 51 and 60 years and the male to
female ratio was 1.63:1. Fifteen patients (10%) were culture positive. The culture positivity was significantly
higher in acute lymphocytic leukemia (ALL) than in non-ALL patients (p = 0.03). There was significant associa-
tion of candidaemia with leucopenia, chemotherapeutic drugs, corticosteroids and presence of indwelling
devices. Duration of disease (p = 0.032) and duration of hospitalization (p = 0.003) were significantly prolonged
in culture positive patients. C. tropicalis was the commonest isolate (46.67%), with non- Candida albicans out-
numbering C. albicans in all categories of hematological malignancies (2.75:1). All isolates of C. albicans were
uniformly sensitive to all the azoles, but only 50% were sensitive to amphotericin B and none to nystatin and
flucytosine.
CONCLUSIONS: This observational study identifies ALL and chronic lymphocytic leukemia (CLL) as the forms
of hematological malignancy predominantly associated with candidemia; specifies risk factors and chemother-
apeutic agents predisposing patients towards its occurrence; reports a preponderance of C. tropicalis among the
causative agents and finds voriconazole to be the most effective antifungal agent against the recovered isolates.
This information could assist in tailoring prophylactic and therapeutic antifungal practices for this infection,
according to local epidemiological and mycological characteristics.
KEYWORDS: Hematological malignancies; Candida infections; Antifungal resistance; Candida tropicalis; Non-Candida
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t CANDIDEMIA IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIESThe threat of opportunistic Candida infectionshas been increasing in contemporary healthcare scenarios,1–4 with patients suffering
from hematological malignancies being particularly
vulnerable to such infections.5–7 Apart from being
widely prevalent, opportunistic Candida infections
are often acutely progressive, difﬁcult to diagnose,
and are associated with increased hospital stays and
high mortality rates.3 Antifungal resistance, which
has arisen because of the increasing prophylactic use
of ﬂuconazole and the relative rise in the proportion
of non-Candida albicans species, has also been evolving
lately as a major challenge in the management of
Candida infections.2,8–10 The increasing isolation of
non-C. albicans infections earlier during the course
of cytotoxic chemotherapy11 necessitates an evaluation
of the antifungal susceptibility proﬁle of Candida iso-
lates, to ensure the optimal choice of prophylactic and
therapeutic antifungal agents in patients with hemato-
logical malignancies.
Although India has a high prevalence of oppor-
tunistic Candida infections, representative data on
the epidemiological and mycological characteristics
of these infections are virtually nonexistent in vast
stretches of the country. Moreover, owing to the geo-
graphical and temporal variation often observed in the
distribution of Candida species, there is a need to
investigate and monitor local epidemiological patterns
of candidemia in the context of the immense ecogeo-
graphical diversity observed in India. In our previous
study on the proﬁle of Candida infections in adult
intensive care unit (ICU) patients, we have observed
ongoing cancer chemotherapy to be an important risk
factor for the development of candidemia at our cen-
ter.12 In view of this initial observation and consider-
ing the paucity of data from Indian centers on this
subject, we undertook this study with the objective
of exploring the epidemiological and mycological char-
acteristics of candidemia occurring in patients suffer-
ing from hematological malignancies, and thereby
ascertaining the contributing risk factors and deter-
mining the antifungal susceptibility proﬁle of the
recovered Candida isolates.
original research reporMATERIALS AND METHODS
This prospective observational study was conducted
on consecutive patients suffering from hematological
malignancy who reported to the Medical Oncology
Unit of a tertiary-care teaching hospital in the
Himalayan region of northern India with a febrile
episode during the 18-month study period, fromNovember 2010 to April 2012. A febrile episode
was deﬁned, for the purpose of this study, by a
recorded oral temperature exceeding 38 C
(100.4F) in a patient presenting with febrile symp-
toms. A chemotherapeutic regimen was planned for
every recruited patient for the management of the
underling hematological malignancy and the patients
were advised to report to the hospital for their sched-
uled courses of chemotherapy/radiotherapy or fol-
lowing the development of any emergency
condition. Monitoring of disease activity and
chemotherapy-related adverse effects was done at
every scheduled visit, according to standard guideli-
nes, using blood counts, liver function tests, kidney
function tests, bone marrow examination, and imag-
ing wherever required. The febrile episode was inves-
tigated for the development of candidemia by
performing blood culture. Single blood samples
(5 mL in case of adults and 2 mL in case of children)
were drawn with proper aseptic precautions and
inoculated into biphasic brain heart infusion med-
ium. The blood culture bottles were incubated for
7 days at 25 C and were tilted for half an hour every
day until the appearance of fungal colonies on the
solid phase. Isolates recovered were subcultured on
Sabouraud’s dextrose agar (SDA) and typical
Candida colonies, characterized by smooth, creamy,
and pasty appearance on SDA, were speciated using
standard tests such as germ tube test, sugar assimila-
tion test, sugar fermentation test, microscopic mor-
phology on corn meal agar, and color production
on CHROMagar media. Recovery of any Candida
species from blood cultures was taken as evidence
of candidemia. The Candida isolates were also sub-
jected to antifungal susceptibility testing using the
disk diffusion method on Müller–Hinton agar with
2% glucose and 0.5 lg/mL methylene blue, according
to the Clinical and Laboratory Standards Institute
guideline M-44A.13 Susceptibility testing was per-
formed with commercially procured antifungal disks
(HiMedia, Mumbai, India) against ﬂuconazole
(25 lg), clotrimazole (10 lg), voriconazole (1 lg),
amphotericin B (100 U), nystatin (50 lg), and ﬂucy-
tosine (1 lg). For interpretation of sensitivity, zone
sizes recommended by disk manufacturers were con-
sidered. American Type Culture Collection (ATCC)
strains C. albicans 90028, Candida parapsilosis 22019,
and Candida krusei 6258 were used as controls.
The study protocol was reviewed and approved by
the Institutional Ethics Committee and written
informed consent was recorded from each of the
recruited patients.Hematol Oncol Stem Cell Ther 8(3) Third Quarter 2015
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A web-based calculator (http://www.stat.ubc.ca/
~rollin/stats/ssize/) was used for calculating sample
size. We presumed a candidemia prevalence of 1–
6% in the population and aimed at detecting an
approximate difference of 5% in the prevalence of can-
didemia in patients with hematological malignancies,
with a desired power of 0.8 and a value of .05. The
optimal sample size calculated was between 53 and
172. The Chi-square test was used for comparing cat-
egorical variables and the independent t test was used
for comparing continuous variables between candi-
demic and noncandidemic cases. Mean, standard devi-
ation (SD), and odds ratio were calculated according
to standard deﬁnitions. SPSS version 21.0 (SSPS
Inc., Chicago, IL, USA) was used for analysis and
p < .05 was considered signiﬁcant.RESULTS
A total of 150 patients (93 men) were recruited to
this study. The mean (±SD) age of the study group
was 40 (±21) years. The majority of the patients
(n = 27; 15 men) were between 51 and 60 years of
age and 16 patients (10.66%; 10 men) were in the
1st decade of life. Seven forms of hematological malig-
nancy were observed among the recruited patients,
with acute leukemia being the predominant form
(n = 75). Among patients with acute leukemia, 39
(26%) were suffering from acute myeloid leukemia
(AML) and 36 (24%) had acute lymphocytic leukemia
(ALL).
Fifteen patients (10 men) had positive culture for
candidemia, thereby recording a prevalence of 10%
candidemia cases among febrile patients with hemato-
logical malignancy. The mean (±SD) age of the
culture-positive candidemic patients was 30 (±23)Table 1. Distribution of candidemic patients across the spectrum of hem
Hematological malignancy No. of patients
Acute lymphocytic leukemia 36
Chronic lymphocytic leukemia 13
Acute myeloid leukemia 39
Non-Hodgkin's lymphoma 26
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age and sex distribution of culture-positive and
culture-negative patients. However, culture positivity
for candidemia was signiﬁcantly higher among ALL
patients (odds ratio = 3.2; p = .03). Candidemia was
not observed among patients with multiple myeloma
(n = 14) and Hodgkin’s lymphoma (n = 4; Table 1).
We next sought to determine the risk factors that
predisposed the patients with hematological malig-
nancy for candidemia. We observed a signiﬁcantly
higher proportion of leukopenia (white blood cell
count < 4000 cells/mm3) among candidemic patients
(odds ratio = 7.3; p = 0.00015). Among iatrogenic
factors, administration of chemotherapeutic drugs
(odds ratio = 16.1; p = 0.0066), use of corticosteroids
(odds ratio = 4.7; p = 0.003892), and presence of
indwelling devices such as urinary catheter, central
venous catheter, and nasogastric tube (odds
ratio = 4.6, p = 0.0038; odds ratio = 4.5, p = 0.015;
and odds ratio = 6.8, p = 0.023, respectively) were
also found to be signiﬁcantly common among the
culture-positive patients. Duration of disease
(p = 0.032) and duration of hospitalization
(p = 0.003) were also signiﬁcantly prolonged in
culture-positive patients (Table 2).
We also explored the possible association of differ-
ent chemotherapeutic regimens with the occurrence of
candidemia. The recruited patients in our study
received a total of 13 chemotherapeutic regimens, of
which there was one regimen for AML; three
regimens for ALL; two each for chronic lymphocytic
leukemia (CLL), chronic myeloid leukemia, non-
Hodgkin’s lymphoma, and multiple myeloma; and
one regimen for Hodgkin’s lymphoma. Four of these
13 regimens were found to be signiﬁcantly associated
with candidemia in our patients. The regimens found
to be associated with candidemia were (a) cytosineatological malignancies.










Table 2. Distribution of potential risk factors among the recruited patients.
Risk factors Total No. of patients Candidemic patients p
Present (%) Absent (%) Present (%) Absent (%)
Leukopenia 39 (26) 111 (74) 10 (66.67) 5 (33.33) 0.00015
Neutropenia 100 (66.67) 50 (33.33) 12 (80) 3 (20) 0.24
Anemia 77 (51.33) 73 (48.67) 9 (60) 6 (40) 0.47
Steroids 50 (33.33) 100 (66.67) 10 (66.67) 5 (33.33) 0.00389
Chemotherapy 104 (69.33) 46 (30.66) 15 (100) 0 0.0066
Radiotherapy 16 (10.67) 134 (89.33) 2 (13.33) 13 (86.67) 0.72
Indwelling devices
IVC 74 (49.33) 76 (50.67) 8 (53.33) 7 (46.67) 0.74
Urinary catheter 35 (23.33) 115 (76.67) 8 (53.33) 7 (46.67) 0.0038
CVC 14 (9.33) 136 (90.67) 4 (26.67) 11 (73.33) 0.015
Nasogastric tube 5 (3.33) 145 (96.67) 2 (13.33) 13 (86.67) 0.023
Parenteral nutrition 18 (12) 132 (88) 3 (20) 12 (80) 0.31
CVC = central venous catheter; IVC = intravenous catheter.
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4.0, p = .047); (b) cyclophosphamide and/or vin-
cristine, doxorubicin/daunorubicin, L-asparaginase,
and prednisolone (ALL; odds ratio = 4.1,
p = 0.023326); (c) mercaptopurine and prednisolone
(ALL; odds ratio = 10.2, p = 0.006873); (d)
cyclophosphamide, vincristine, and prednisolone
(CLL; odds ratio = 6.8, p = 0.022). Studying the
association with individual chemotherapeutic drugs,
we observed signiﬁcantly higher occurrence of can-
didemia following the use of cyclophosphamide (odds
ratio = 3.8, p = 0.01096), vincristine (odds ratio =
4.0, p = 0.0086), L-asparaginase (odds ratio = 4.1,
p = 0.023), doxorubicin (odds ratio = 3.4, p =
0.025), and mercaptopurine (odds ratio = 4.1,
p = 0.0068).
Candida tropicalis was the most common isolate
recovered in our study (46.67%), with non-C. albicans
outnumbering C. albicans in all categories of hemato-
logical malignancies (2.75:1). C. tropicalis was the only
species of Candida isolated from patients with AML
and chronic myeloid leukemia. Apart from
C. tropicalis and C. albicans, one isolate each of
Candida glabrata, C. krusei, C. parapsilosis, and
Candida dubliniensis were recovered from the patients.
Because C. krusei is intrinsically resistant to azoles, it
was not analyzed for sensitivity to the azole group of
drugs. While all isolates of C. albicans, C. parapsilosis,
and C. dubliniensis were uniformly sensitive to all theazoles tested, one isolate (14.3%) of C. tropicalis was
resistant to ﬂuconazole and clotrimazole. Sensitivity
to voriconazole was also observed for all the isolates,
apart from C. glabrata (Table 3). Quality control of
the used ATCC strains was performed by
determining their minimum inhibitory concentration
(MIC) to the antifungal agents used in the
study. C. parapsilosis 22019 demonstrated MIC
of 0.25–1.0 lg/mL for amphotericin B,
0.12–0.5 lg/mL for ﬂucytosine, 2.0–8.0 lg/mL for
ﬂuconazole, and 0.016–0.064 lg/mL for voricona-
zole. The corresponding MIC ranges for C. krusei
ATCC 6258 were 0.5–2.0 lg/mL, 4.0–16 lg/mL,
16.0–64.0 lg/mL, and 0.06–0.25 lg/mL.DISCUSSION
In this paper, we report a prevalence of 10% for can-
didemia among febrile hematological malignancy
patients attending a tertiary-care teaching hospital in
the Himalayan region of northern India. Among the
various forms of hematological malignancy, we
observed a signiﬁcantly higher predisposition to can-
didemia in ALL. We also specify risk factors and
chemotherapeutic regimens signiﬁcantly associated
with the occurrence of candidemia in these patients.
C. tropicalis was the commonest species recovered in
our patients and voriconazole was the most effective
antifungal agent.Hematol Oncol Stem Cell Ther 8(3) Third Quarter 2015
Table 3. Results of antifungal susceptibility tests by disk diffusion method.
Isolates No. (%) Sensitive (%)
Flu Cc Vo 5-FC Nys AmpB
Candida albicans 4 (26.7) 4 (100) 4 (100) 4 (100) 0 0 2 (50)
Candida tropicalis 7 (46.7) 6 (85.7) 6 (85.7) 7 (100) 0 3 (42.9) 7 (100)
Candida glabrata 1 (6.7) 0 0 0 0 0 0
Candida parapsilosis 1 (6.7) 1 (100) 1 (100) 1 (100) 0 0 1 (100)
Candida krusei 1 (6.7) 0 0 0 0 1 (100) 0
Candida dubliniensis 1 (6.7) 1 (100) 1 (100) 1 (100) 0 1 (100) 1 (100)
5-FC = 5-flucytosine; AmpB = amphotericin B; Cc = clotrimazole; Flu = fluconazole; Nys = nystatin; Vo = voriconazole.
CANDIDEMIA IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES original research reportThe prevalence of candidemia among patients with
hematological malignancy has been found to vary
widely between 1.6% and 22.9%5,14–16 depending on
the patient proﬁle studied, geographical location
involved, and diagnostic criteria used. Although there
have been reports from Indian centers on the spec-
trum of bacterial infections occurring in hematological
malignancies,17,18 these did not report the epidemio-
logical and mycological characteristics of candidemia.
Our ﬁndings, with regard to the increased occurrence
of candidemia in acute leukemia patients, are consis-
tent with previous reports from other centers across
the globe.5,19,20 However, the relatively high fre-
quency of candidemia observed in this study in CLL
patients was not in sync with earlier studies.5 This rel-
atively high frequency could be due to late presenta-
tion of such patients in our population, which could
lead to myelophthisis and subsequent neutropenia.
Several risk factors identiﬁed by us, namely, leukope-
nia, presence of indwelling devices, use of corticos-
teroids, have also been previously reported in earlier
studies to be signiﬁcantly associated with candidemia
in patients with hematological malignan-
cies.14,15,19,21,22 However, to the best of our knowl-
edge, this is the ﬁrst study to have evaluated the
relative risk of candidemia associated with individual
chemotherapeutic regimens administered in hemato-
logical malignancies. Mucosal damage, due to anti-
cancer chemotherapy, is considered to be a major
factor contributing to invasive candidiasis originating
from the gastrointestinal tract.23 Identiﬁcation of
speciﬁc chemotherapeutic regimens, which add to
the vulnerability to candidemia, could help in risk
stratiﬁcation and decision making regarding use of
empirical antifungal prophylaxis in selected subsets
of patients.Hematol Oncol Stem Cell Ther 8(3) Third Quarter 2015Geographical variation is an important feature in
the species distribution of Candida. In accordance
with trends observed in majority of studies across
the globe,24–30 shift in the species distribution of
Candida has been noted in several major Indian hos-
pitals. Non-C. albicans have been isolated from 30% to
90% of invasive candidiasis cases.26–32 However, in
recent studies from our center conducted on adult
and neonatal ICU patients, we have observed a pre-
dominance of C. albicans among the recovered iso-
lates.12,33 The ﬁnding of C. tropicalis being the most
frequently recovered species in this study is indicative
of a unique mycological trait speciﬁc to the epidemiol-
ogy of candidemia in hematological malignancies.
Interestingly, previous papers have reported C. tropi-
calis to be a common isolate in hematological malig-
nancies, with C. albicans being more frequently
observed in patients with solid organ tumors.34
Moreover, similar to our ﬁndings, other studies
from India, Singapore, and Taiwan have reported
C. tropicalis to be the commonest non-C. albicans
species35–37; by contrast, C. glabrata is reported to
be the commonest non-C. albicans species isolated
from the rest of the world.24,32,38–40
The prophylactic use of ﬂuconazole is a standard
practice in hematological malignancy patients under-
going chemotherapy and most of the patients
recruited in this study were receiving antifungal pro-
phylaxis. This could be a cause for the species shift
toward non-albicans candidemia and the alarming
degree of antifungal resistance observed in our study.
Our study suffered from several limitations. First,
because we used culture positivity in brain heart infu-
sion broth as the criterion for diagnosing candidemia,
the estimated prevalence of 10% could be an
underassessment of the actual prevalence. Employing103
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more sensitive systems such as automated blood cul-
ture techniques or use of novel biomarkers (e.g.,
1,3-b-D-glucan) might have resulted in a higher diag-
nostic yield. Second, the relatively small number of
patients in some of the subgroups of hematological
malignancy (e.g., Hodgkin’s lymphoma) makes our
study inadequately powered to assess the actual preva-
lence of candidemia in these subgroups. Third, the
relatively less number of C. albicans isolates could lead
to seemingly high proportion of resistance to ampho-
tericin B. Finally, we did not test our isolates for sus-
ceptibility to echinocandins, primarily because this
group of antifungal agents was not in use at our center
due to affordability issues.CONCLUSION
We observe that this observational study identiﬁes
ALL and CLL as the forms of hematologicalmalignancy predominantly associated with can-
didemia. In addition, risk factors and chemotherapeu-
tic agents predisposing patients toward its occurrence
were speciﬁed. We have also noted a preponderance
of C. tropicalis among the causative agents and identi-
ﬁed voriconazole to be the most effective antifungal
agent against the recovered isolates. This study could
assist in alerting clinicians about the prevalence of
candidemia in hematological malignancy and also in
tailoring prophylactic and therapeutic antifungal prac-
tices, according to local epidemiological and mycolog-
ical characteristics.CONFLICTS OF INTEREST
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